Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002203 · ClinicalTrials.gov registry record · NA
A Study of Two Anti-HIV Drug Combinations
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002203: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002203 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002203, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI. This study also examines how well patients follow the dosing schedules for these drugs. Doctors believe that taking Combivir plus a PI may be as effective as taking 3TC plus ZDV plus a PI.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Lamivudine/Zidovudine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002203 record still lists
NCT00002203 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002203 about?
NCT00002203 is a clinical study titled "A Study of Two Anti-HIV Drug Combinations". The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI. This study also examines how well patients follow the dosing schedules for these drugs...
What is the current status of trial NCT00002203?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002203?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Lamivudine/Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00002203?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.